Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-20

Clinical Trial Update: Phase 4 COPD and Suboptimal Inspiratory Flow Rate [Phase 4]

View source ↗

Summary

Phase 4 COPD trial update examining the impact of suboptimal inspiratory flow rate, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Revefenacin (revefenacin)

Snippet

Sponsor: Theravance Biopharma | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2024-12-20